Evidence map›Paper›PMID 37353225›Full record

ArticleThe Journal of infectious diseases2023

Rapid Antigen and Antibody Microfluidic Immunofluorescence Assays Compared to Culture, PCR, and Laboratory Reference Tests: Performance in a Longitudinal Cohort.

Ronit R Dalmat, Linhui Hao, Roshni Prabhu, Elena Rechkina, Daphne Hamilton, Matthew H Ikuma, Marie Bauer, Michael Gale, Jason L Cantera, Alexey S Ball and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ronit R DalmatInternational Clinical Research Center, Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-6959-0817
Linhui HaoDivision of Allergy and Infectious Diseases, Department of Medicine, School of Medicine, University of Washington, Seattle, Washington, USA.
Roshni PrabhuInternational Clinical Research Center, Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, Washington, USA.
Elena RechkinaInternational Clinical Research Center, Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, Washington, USA.
Daphne HamiltonInternational Clinical Research Center, Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, Washington, USA.
Matthew H IkumaInternational Clinical Research Center, Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, Washington, USA.
Marie BauerInternational Clinical Research Center, Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, Washington, USA.
Michael GaleDepartment of Immunology, Center for Innate Immunity and Immune Disease, University of Washington, Seattle, Washington, USA.
Jason L CanteraGlobal Health Labs, Bellevue, Washington, USA.
Alexey S BallGlobal Health Labs, Bellevue, Washington, USA.
Benjamin D GrantGlobal Health Labs, Bellevue, Washington, USA.
Paul K DrainInternational Clinical Research Center, Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-9569-4097

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
University of Washington Arboviral Research Network (UWARN)U01AI151698 · NIAID · UNIVERSITY OF WASHINGTON · PI Michael Gale, PETER MACGARR RABINOWITZ · 2020 to 2026
$13.3M
NIAID NIH HHS U01 AI151698NIH HHS AI151698NIH HHS P51 OD010425
6 · The paper itself

Abstract

We evaluated the performance of rapid antigen (RAg) and antibody (RAb) microfluidic diagnostics with serial sampling of 71 participants at 6 visits over 2 months following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Rapid tests showed strong agreement with laboratory references (κAg = 81.0%; κAb = 87.8%). RAg showed substantial concordance to both virus growth in culture and PCR positivity 0-5 days since symptom onset (κAg-culture = 60.1% and κAg-PCR = 87.1%). PCR concordance to virus growth in culture was similar (κPCR-culture = 70.0%), although agreement between RAg and culture was better overall (κAg-culture = 45.5% vs κPCR-culture = 10.0%). Rapid antigen and antibody testing by microfluidic immunofluorescence platform are highly accurate for characterization of acute infection.

Indexed as

COVID-19SARS-CoV-2AntibodiesClinical Laboratory TechniquesCOVID-19 TestingHumansMicrofluidicsPolymerase Chain ReactionSensitivity and SpecificityAntibodiesantigen testCOVID-19infectivitylongitudinalrapid diagnostic testSARS-CoV-2serial testing

Identifiers

PMID37353225
PMCPMC10582900

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.